WELCOME TO The PHARMACEUTICAL REPORT
Axentis Pharma AG
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Twelve Consulting Group, | February 11, 2022
Twelve Consulting Group, a consultancy firm specializingin designing and delivering cloud-based solutions, has formalized its partnership with Celonis, the global leader in execution management.
This partnership combines Twelve CG’s technology consulting expertise with Celonis’ market leading process mining and execution management capabilities, enabling customers to optimize their business operations, identify inefficiencies and unlock their full execution capacity.
TrialCard | August 31, 2021
TrialCard Incorporated today announced the launch of Engage HCP by TrialCard, a new expanded suite of services that serves as a complement to a biopharma brand's field teams, while delivering measurable results in brand reach, lead generation, and market share growth.
Engage HCP by TrialCard is designed to offer a flexible array of services that can serve as standalone teams or be used to bolster the efforts of existing field teams. Engage HCP offers HCP engagement servi...
Telix Pharmaceuticals Limited | April 11, 2022
Telix Pharmaceuticals Limited announces that it has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma.
Olaratumab was originally developed by Lilly as a monoclonal antibody targeting Pl...
VIEWS AND ANALYSIS, PHARMA TECH
Virpax Pharmaceuticals | December 15, 2022
Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and viral barrier indications, today announced that it has received pre-Investigational New Drug application guidance from the U.S. Food and Drug Administration for NobrXiol™, the Company’s product candidate for the delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utili...
Research, PHARMACY MARKET
Research, PHARMA TECH
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE